Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis

OBJECTIVE: To determine the extent to which disease duration, alone or in combination with other baseline clinical and non-clinical factors, explains variations in outcome of tocilizumab initiated in biologic-naïve patients with established RA. METHODS: In this pooled analysis of phase 3 and 4 clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubbert-Roth, Andrea, Aletaha, Daniel, Devenport, Jenny, Sidiropoulos, Paris N, Luder, Yves, Edwardes, Michael D, Jacobs, Johannes W G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850526/
https://www.ncbi.nlm.nih.gov/pubmed/32844216
http://dx.doi.org/10.1093/rheumatology/keaa259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850526/
https://www.ncbi.nlm.nih.gov/pubmed/32844216
http://dx.doi.org/10.1093/rheumatology/keaa259

Ejemplares similares